These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 32972983)
21. Identification of Celastramycin as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension. Kurosawa R; Satoh K; Kikuchi N; Kikuchi H; Saigusa D; Al-Mamun ME; Siddique MAH; Omura J; Satoh T; Sunamura S; Nogi M; Numano K; Miyata S; Uruno A; Kano K; Matsumoto Y; Doi T; Aoki J; Oshima Y; Yamamoto M; Shimokawa H Circ Res; 2019 Jul; 125(3):309-327. PubMed ID: 31195886 [TBL] [Abstract][Full Text] [Related]
22. Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. da Silva Gonçalves Bós D; Van Der Bruggen CEE; Kurakula K; Sun XQ; Casali KR; Casali AG; Rol N; Szulcek R; Dos Remedios C; Guignabert C; Tu L; Dorfmüller P; Humbert M; Wijnker PJM; Kuster DWD; van der Velden J; Goumans MJ; Bogaard HJ; Vonk-Noordegraaf A; de Man FS; Handoko ML Circulation; 2018 Feb; 137(9):910-924. PubMed ID: 29167228 [TBL] [Abstract][Full Text] [Related]
23. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation. Tian W; Jiang X; Sung YK; Shuffle E; Wu TH; Kao PN; Tu AB; Dorfmüller P; Cao A; Wang L; Peng G; Kim Y; Zhang P; Chappell J; Pasupneti S; Dahms P; Maguire P; Chaib H; Zamanian R; Peters-Golden M; Snyder MP; Voelkel NF; Humbert M; Rabinovitch M; Nicolls MR Circulation; 2019 Oct; 140(17):1409-1425. PubMed ID: 31462075 [TBL] [Abstract][Full Text] [Related]
24. Maresin 1 intervention reverses experimental pulmonary arterial hypertension in mice. Li H; Li X; Hao Y; Wu C; Fu Y; Su N; Chen H; Ying B; Wang H; Su L; Cai H; He Q; Cai M; Sun J; Lin J; Scott A; Smith F; Huang X; Jin S Br J Pharmacol; 2022 Nov; 179(22):5132-5147. PubMed ID: 35764296 [TBL] [Abstract][Full Text] [Related]
25. Targeting RUNX1 as a novel treatment modality for pulmonary arterial hypertension. Jeong EM; Pereira M; So EY; Wu KQ; Del Tatto M; Wen S; Dooner MS; Dubielecka PM; Reginato AM; Ventetuolo CE; Quesenberry PJ; Klinger JR; Liang OD Cardiovasc Res; 2022 Dec; 118(16):3211-3224. PubMed ID: 35018410 [TBL] [Abstract][Full Text] [Related]
29. Notch2 suppression mimicking changes in human pulmonary hypertension modulates Notch1 and promotes endothelial cell proliferation. Sahoo S; Li Y; de Jesus D; Sembrat J; Rojas MM; Goncharova E; Cifuentes-Pagano E; Straub AC; Pagano PJ Am J Physiol Heart Circ Physiol; 2021 Sep; 321(3):H542-H557. PubMed ID: 34296965 [TBL] [Abstract][Full Text] [Related]
30. Farnesyl diphosphate synthase regulated endothelial proliferation and autophagy during rat pulmonary arterial hypertension induced by monocrotaline. Jin T; Lu J; Lv Q; Gong Y; Feng Z; Ying H; Wang M; Fu G; Jiang D Mol Med; 2022 Aug; 28(1):94. PubMed ID: 35962329 [TBL] [Abstract][Full Text] [Related]